Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00102089 · ClinicalTrials.gov registry record · Phase 1

HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers

A Phase 1 study of Healthy and HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Compiled by PlainTrial · August 8, 2026

Completed
Registry status: Phase 1
Development phase: 32
Enrollment target: 1
Study location

NCT00102089: Completed Phase 1 study of Healthy and HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00102089 is a Phase 1 study of Healthy and HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 32 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00102089, a Phase 1 study of Healthy and HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status: Phase 1
Development phase: 32 participants
Enrollment target: 1
Study location

Study Summary

This study will test the safety and side effects of an experimental vaccine booster against HIV. A vaccine is a substance given to try to create immunity or resistance to a disease or infection. The vaccine used in this study is called VRC-HIVADV014-00-VP. It is made from an adenovirus (a common virus that causes upper respiratory infections) that contains DNA (genetic material) of three HIV proteins. Injected into a human, the viral DNA instructs the body to make small amounts of some HIV proteins. VRC-HIVADV014-00-VP will be given to people who previously received a vaccine called VRC-HIVDNA009-00-VP under NIH protocol 03-I-0022. Important: Study participants cannot catch an adenovirus infection or HIV or AIDS from the vaccine or any proteins made from it. Healthy normal volunteers who participated in NIH protocol 03-I-0022 may be eligible for this study. They must have completed three injections of 4 mg or 8 mg of VRC-HIVDNA009-00-VP without experiencing a serious side effect that was possibly related to the vaccine. Candidates are screened with a medical history, clinical evaluation, blood and urine tests, and HIV and pregnancy counseling. Participants receive one injection of VRC-HIVADV014-00-VP the day they enroll in the study (study day 0). They are observed for at least 30 minutes after immunization. At home, they record their temperature and any symptoms they may experience, including any effects at the injection site, for 5 days and call a study nurse 1 or 2 days after the injection. They immediately report any symptoms to the clinic staff and, if necessary, come to the clinic for an examination. Participants have five additional clinic visits during the study, at weeks 2, 4, 6, 12 and 24, each lasting about 2 hours. At each visit, they are checked for health changes or problems and are asked about medications they are taking. Blood is drawn for immune function testing, HLA typing (a genetic test of immune system markers), and other genetic factors. A u

Conditions Studied

Healthy HIV Infections

Interventions

DRUG VRC-HIVADV014-00-VP
BIOLOGICAL VRC-HIVADV014-00-VP booster

Study Locations (1)

Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

Field	Value
Enrollment Target	32 participants
Start Date	2005-01-18
Est. Completion	2007-10-10
Phase	Phase 1

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00102089 record still lists

NCT00102089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which VRC-HIVADV014-00-VP is the first listed.

NCT00102089 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00102089 about?

NCT00102089 is a clinical study titled "HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers". This study will test the safety and side effects of an experimental vaccine booster against HIV. A vaccine is a substance given to try to create immunity or resistance to a disease or infection. The vaccine used in this study is called VRC-HIVADV014-00-VP. It is made from an adenovirus (a common vir...

What is the current status of trial NCT00102089?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2005-01-18. Estimated completion is 2007-10-10.

What conditions does trial NCT00102089 study?

This clinical trial studies the following conditions: Healthy, HIV Infections.

What interventions are being tested in trial NCT00102089?

The interventions under investigation include: VRC-HIVADV014-00-VP (DRUG), VRC-HIVADV014-00-VP booster (BIOLOGICAL).

Who is sponsoring clinical trial NCT00102089?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00102089 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00102089's enrollment target sits among peer trials

32 647th of 1090 higher than 418 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00102089, the US trial registry maintained by the National Library of Medicine. NCT00102089 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.